Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (775,000)	$ (494,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock option compensation expense	488,000	256,000
Common stock issued for services	135,000	207,000
Amortization of right-of-use operating lease assets	24,000	0
Interest expense related to amortization of the discount on note payable	0	3,000
Fair value of warrant issued for interest	0	30,000
Loss on investment in South Korean joint venture	1,000	6,000
Depreciation expense	36,000	22,000
Changes in assets and liabilities:
Accounts receivable	139,000	(316,000)
Inventories	(98,000)	(17,000)
Prepaid expenses and other assets	(58,000)	25,000
Deposits	109,000	(71,000)
Contract liabilities	(42,000)	4,000
Lease liability, net	(19,000)	4,000
Net cash provided by (used in) operating activities	481,000	(43,000)
Cash flows from investing activities
Equipment purchases	(863,000)	(48,000)
Net cash used in investing activities	(863,000)	(48,000)
Cash flows from financing activities
Proceeds from sale of common stock, net of commissions	488,000	800,000
Proceeds from warrant exercise	75,000	0
Repayment of debt obligations	(5,000)	(50,000)
Repayment by Clyra debt obligations	0	(15,000)
Proceeds from sale of Clyra Medical preferred stock	0	225,000
Net cash provided by financing activities	1,083,000	1,510,000
Net effect of foreign currency translation	96,000	(6,000)
Net change in cash	797,000	1,413,000
Cash and cash equivalents at beginning of period	3,539,000	1,851,000
Cash and cash equivalents at end of period	4,336,000	3,264,000
Supplemental disclosures of cash flow information
Interest	12,000	15,000
Income taxes	0	5,000
Short-term lease payments not included in lease liability	12,000	13,000
Non-cash investing and financing activities
Equipment added using capital lease	0	80,000
Allocation of noncontrolling interest	399,000	467,000
Preferred Series A Dividend	86,000	0
Conversion of Clyra Common Stock to BioLargo Common Stock [Member]
Non-cash investing and financing activities
Conversion of Clyra common stock to BioLargo common stock	0	100,000
BETI Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock, net of commissions	50,000	550,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock, net of commissions	475,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	252,000	284,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	$ 289,000	$ 14,000